After applying the PI3K kinase inhibitor LY294002 to inhibit the activity of AKT in intestinal DCs, POL-P3b further inhibited AKT activity, indicating that POL-P3b exerts anti-tumor effects by activating the TLR4-PI3K/AKT signalling pathway within DCs to exert anti-tumor effects. This evidence concerns the gene TLR4 and neoplasm.